The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Rheumatology Therapeutics Market Between 2026 And 2030?
The rheumatology therapeutics market has experienced consistent expansion over recent years. Forecasts indicate a rise from $44.18 billion in 2025 to $46.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.5%. Historically, this expansion has been driven by factors such as the rising prevalence of rheumatoid arthritis and osteoarthritis, enhanced accessibility to nsaids and corticosteroids, better detection of rheumatic conditions, increasing healthcare access in established markets, and an uptick in the adoption of conventional synthetic dmards.
The rheumatology therapeutics market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $54.16 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. During the forecast period, several factors will drive this growth, including the escalating demand for biologic DMARDs, an expanding elderly population afflicted with chronic joint conditions, enhanced recognition of the importance of early diagnosis and intervention, the proliferation of targeted synthetic DMARDs, and increased spending on managing chronic diseases within healthcare. Key trends anticipated in the upcoming period encompass the increasing embrace of biologic and targeted DMARDs, a move towards prompt and intensive disease management, a surge in the application of combination therapies for rheumatic conditions, a heightened emphasis on achieving prolonged disease remission, and the broadening of personalized therapeutic strategies within rheumatology.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp
What Drivers Are Influencing The Rheumatology Therapeutics Market?
An increasing incidence of autoimmune conditions is anticipated to drive expansion in the rheumatology therapeutics market. An autoimmune disorder occurs when the immune system erroneously targets and harms the body’s own tissues. The widespread occurrence of autoimmune diseases is on the rise, attributed to a blend of genetic predispositions, environmental influences, and lifestyle choices, alongside heightened public awareness and advancements in diagnostic methods. Treatments in rheumatology are essential for autoimmune diseases to control inflammation, reduce symptoms, and prevent the harm to joints and tissues that results from the immune system’s assault on the body. As an illustration, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that approximately 514,000 individuals in Australia, representing 2.0% of its populace, were estimated to be afflicted with rheumatoid arthritis in 2022. In 2023, rheumatoid arthritis was responsible for 2.0% of the overall disease burden and contributed to 16% of the burden across all musculoskeletal conditions. Consequently, the increasing occurrence of autoimmune diseases is stimulating expansion in the rheumatology therapeutics market.
Which Market Segments Are Examined In The Rheumatology Therapeutics Market Study?
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications
Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics
Which Trends Are Influencing The Rheumatology Therapeutics Market?
Companies primarily engaged in the rheumatology therapeutics market are innovating solutions, such as intravenous (IV) formulations, to boost treatment efficacy and patient convenience. An intravenous (IV) formulation is a medicinal compound or substance administered directly into a vein using a needle or catheter. For example, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, revealed that the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This specific Cosentyx formulation is uniquely sanctioned for treating adults afflicted with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It operates by precisely targeting and inhibiting interleukin-17A (IL-17A) and stands as the sole non-tumor necrosis factor alpha (TNF-α) IV treatment accessible for these particular conditions.
Who Are The Primary Competitors In The Rheumatology Therapeutics Market?
Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sanofi SA, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Janssen Biotech, Genentech Inc., Galapagos NV
Read the full rheumatology therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Rheumatology Therapeutics Market?
North America was the largest region in the rheumatology therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Rheumatology Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp
Browse Through More Reports Similar to the Global Rheumatology Therapeutics Market 2026, By The Business Research Company
Rheumatology Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report
Rheumatoid Arthritis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
Rheumatoid Arthritis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model